Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioCryst Partners With Shionogi On Influenza Antiviral In Japan

This article was originally published in The Pink Sheet Daily

Executive Summary

Shionogi gains development and commercialization rights for peramivir in Japan in deal worth up to $130 million plus royalties for BioCryst.

You may also be interested in...



Stock Price Increases Suggest Flu-Oriented Biotechs May Capitalize On Differentiation

Companies like Novavax and Dynavax may enjoy improved financial prospects thanks to the way their differentiated approaches to flu therapy could address future outbreaks.

Stock Price Increases Suggest Flu-Oriented Biotechs May Capitalize On Differentiation

Companies like Novavax and Dynavax may enjoy improved financial prospects thanks to the way their differentiated approaches to flu therapy could address future outbreaks.

BioCryst Compound Ineffective Against Psoriasis In Phase II Dosing Trial

Data show potential against T-cell and B-cell mediated disease, however.

Topics

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel